Insider · CIK 0001190270

PERRY MARK L

Reports to the SEC for 6 companies · SANTA CLARA, CA

sec.gov

Transactions

Companies

Filings

CIK

0001190270

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2024-04-02	NVDANVIDIA CORPS Sale	Director	SSale	−7,000 sh	$887.89	−$6.22M	116,000
2024-02-23	NVDANVIDIA CORPS Sale	Director	SSale	−15K sh	$796.45	−$11.9M	123,000
2023-06-23	NVDANVIDIA CORPA Award	Director	AAward	+650 sh	—	—	13,612
2023-05-26	NVDANVIDIA CORPG Gift	Director	GGift	−2,000 sh	—	—	138,000
2023-05-26	NVDANVIDIA CORPG Gift	Director	GGift	+1,000 sh	—	—	1,000
2023-05-26	NVDANVIDIA CORPG Gift	Director	GGift	+1,000 sh	—	—	1,000
2023-02-27	NVDANVIDIA CORPS Sale	Director	SSale	−6,800 sh	$235.31	−$1.6M	153,200
2023-02-27	NVDANVIDIA CORPS Sale	Director	SSale	−6,100 sh	$236.25	−$1.44M	147,100
2023-02-27	NVDANVIDIA CORPS Sale	Director	SSale	−5,700 sh	$237.36	−$1.35M	141,400
2023-02-27	NVDANVIDIA CORPS Sale	Director	SSale	−1,400 sh	$238.00	−$333K	140,000
2022-10-05	Global Blood Therapeutics, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−37.9K sh	—	—	0
2022-10-05	Global Blood Therapeutics, Inc.Restricted Stock UnitsD Disposition to Issuer	Director	DDisposition to Issuer	−3,600 sh	—	—	0
2022-10-05	Global Blood Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−15K sh	—	—	0
2022-10-05	Global Blood Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−7,500 sh	—	—	0
2022-10-05	Global Blood Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−5,247 sh	—	—	0
2022-10-05	Global Blood Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−5,600 sh	—	—	0
2022-10-05	Global Blood Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−5,600 sh	—	—	0
2022-06-14	Global Blood Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+3,600 sh	—	—	37,865
2022-06-14	Global Blood Therapeutics, Inc.Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−3,600 sh	—	—	0
2022-06-14	Global Blood Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+5,600 sh	—	—	5,600
2022-06-14	Global Blood Therapeutics, Inc.Restricted Stock UnitsA Award	Director	AAward	+3,600 sh	—	—	3,600
2022-06-03	NVDANVIDIA CORPA Award	Director	AAward	+1,438 sh	—	—	12,962
2022-03-18	NVDANVIDIA CORPS Sale	Director	SSale	−1,800 sh	$262.90	−$473K	26,440
2022-03-18	NVDANVIDIA CORPS Sale	Director	SSale	−12.1K sh	$263.67	−$3.19M	14,340
2022-03-18	NVDANVIDIA CORPS Sale	Director	SSale	−2,716 sh	$264.92	−$720K	11,624
2022-03-18	NVDANVIDIA CORPS Sale	Director	SSale	−100 sh	$265.49	−$26.5K	11,524
2021-06-17	Global Blood Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+3,037 sh	—	—	34,265
2021-06-17	Global Blood Therapeutics, Inc.Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−3,037 sh	—	—	0
2021-06-17	Global Blood Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+5,600 sh	—	—	5,600
2021-06-17	Global Blood Therapeutics, Inc.Restricted Stock UnitsA Award	Director	AAward	+3,600 sh	—	—	3,600
2021-06-04	NVDANVIDIA CORPA Award	Director	AAward	+429 sh	—	—	7,060
2021-04-05	NVDANVIDIA CORPS Sale	Director	SSale	−4,704 sh	$556.46	−$2.62M	8,031
2021-04-05	NVDANVIDIA CORPS Sale	Director	SSale	−1,400 sh	$556.98	−$780K	6,631
2020-11-17	MyoKardia, Inc.U Disposition from Tender	Director	UDisposition from Tender	−29.5K sh	—	—	0
2020-11-17	MyoKardia, Inc.Stock Option (Right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−21.8K sh	—	—	0
2020-11-17	MyoKardia, Inc.Stock Option (Right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−11K sh	—	—	0
2020-11-17	MyoKardia, Inc.Stock Option (Right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−11K sh	—	—	0
2020-11-17	MyoKardia, Inc.Stock Option (Right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−11K sh	—	—	0
2020-11-17	MyoKardia, Inc.Stock Option (Right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−6,600 sh	—	—	0
2020-11-17	MyoKardia, Inc.Stock Option (Right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−3,000 sh	—	—	0
2020-06-18	MyoKardia, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+3,000 sh	—	—	3,000
2020-06-18	MyoKardia, Inc.Restricted Stock UnitsA Award	Director	AAward	+1,800 sh	—	—	1,800
2020-06-17	Global Blood Therapeutics, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+4,800 sh	—	—	31,228
2020-06-17	Global Blood Therapeutics, Inc.Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	+4,800 sh	—	—	0
2020-06-17	Global Blood Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+5,247 sh	—	—	5,247
2020-06-17	Global Blood Therapeutics, Inc.Restricted Stock UnitsA Award	Director	AAward	+3,037 sh	—	—	3,037
2020-06-13	MyoKardia, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+2,300 sh	—	—	27,708
2020-06-13	MyoKardia, Inc.Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−2,300 sh	—	—	0
2020-06-13	MyoKardia, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+2,300 sh	—	—	27,708
2020-06-13	MyoKardia, Inc.Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	+2,300 sh	—	—	0

Recent filings

Accepted (ET)
Apr 34
PERRY MARK L0001045810-24-000090
SEC(opens sec.gov)
Feb 274
PERRY MARK L0001045810-24-000040
SEC(opens sec.gov)
Jun 274
PERRY MARK L0001045810-23-000154
SEC(opens sec.gov)
May 314
PERRY MARK L0001045810-23-000099
SEC(opens sec.gov)
Feb 284
PERRY MARK L0001045810-23-000024
SEC(opens sec.gov)
Oct 64
PERRY MARK L0000899243-22-033162
SEC(opens sec.gov)
Jun 164
PERRY MARK L0000899243-22-022903
SEC(opens sec.gov)

Companies

Address

C/O NVIDIA CORPORATION 2701 SAN TOMAS EXPRESSWAY

SANTA CLARA, CA, 95050